COVID-19
Excerpt from the article: Convalescent therapy has been touted as a fast, effective response to COVID-19, but a new therapy by GigaGen Inc. could be even more promising. GIGA-2050, a new class of drug called a recombinant hyperimmune, offers 100-fold higher potency than convalescent serum therapy. “GIGA-2050 is a mix of 12,500 different antibody sequences…
Read More
Excerpt from the article: “In late January, when hospitals in the United States confirmed the presence of the novel coronavirus, health workers knew to watch for precisely three symptoms: fever, cough, and shortness of breath. But as the number of infections climbed, the symptom list began to grow. Some patients lost their sense of smell…
Read More
Excerpt from the Article: “San Diego start-up Truvian Sciences has received federal emergency approval for a blood test that detects COVID-19 antibodies in as little as 10 minutes. Called Easy Check, the portable test will be sold by Truvian to health professionals for about $15 and has an accuracy rate in excess of 98 percent,…
Read More
Excerpt from the article: “Inovio’s stock climbed as much as 15% in pre-market trading Thursday after the Montgomery County biopharmaceutical company announced its Covid-19 vaccine candidate was effective in protecting non-human primates from the virus 13 weeks after the last vaccination. The stock was up more than 6% to $20.73 per share at Thursday’s close.…
Read More
Excerpt from the article: “A single-shot vaccine for COVID-19 being developed by a group of scientists, led by Beth Israel Deaconess Medical Center (BIDMC) immunologist Dan H. Barouch, has proven successful in tests on primates and could begin phase 3 trials as early as September. The results of the tests on the vaccine, developed at…
Read More
Excerpt from the Press Release: “SAN DIEGO–(BUSINESS WIRE)–Selva Therapeutics, Inc. announced today that the company has raised $3 million in a Series A financing round from private investors. The proceeds of the financing will be used to rapidly advance SLV213 into clinical trials as a leading oral drug candidate for the treatment of COVID-19, the…
Read More
Excerpt from the Press Release: “WALTHAM, Mass.–(BUSINESS WIRE)–PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced the launch of a dry blood spot (DBS) based test for SARS-CoV-2 IgG using its GSP®/DELFIA® platform, enabling processing of up to 5,000 samples per day. The finger-prick sample collection device allows for…
Read More
From The Scientist comes this exciting new development in clinical research into COVID-19: “Upon seeing pregnant women sick with COVID-19 at a University of Pennsylvania hospital, researchers there wrote trial protocols for blood transfusions to treat the disease that include expecting mothers. As a translational infectious disease researcher at the University of Pennsylvania Perelman School…
Read More
Excerpt from the Press Release: “WAKEFIELD, MA – July 20, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, reports today receiving new data from ongoing laboratory testing being conducted at a U.S. Regional Biocontainment Laboratory (RBL). The data is helping to inform the planned Phase 2 clinical trial of Brilacidin…
Read More
Excerpt from the article: “Twelve days from the planned start of their Phase III pivotal trial, the executive crew at Moderna has set up the manufacturing base needed to begin production of the first 500,000 doses of their Covid-19 vaccine with plans to feed it into a global supply chain. But the initial batches will…
Read More